Search - tctmd.com

Displaying 21 - 38 of 38

Sort: Relevancy | Date

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

Registry Data Hint at MACE Benefit with Renal Denervation

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

EP’s Diversity Problem: Women, Minorities Remain Underrepresented

News Conference News HRS 2022

EP’s Diversity Problem: Women, Minorities Remain Underrepresented

May 06, 2022

Streamlining EP Consult From the ER Pays Dividends in AF

News Conference News HRS 2022

Streamlining EP Consult From the ER Pays Dividends in AF

May 04, 2022

Ablation May Beat Drugs for Reducing Dementia Risk in AF Patients

News Conference News HRS 2022

Ablation May Beat Drugs for Reducing Dementia Risk in AF Patients

April 30, 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

News Features

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

March 14, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presentation THT 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presenter: Marat Fudim

February 01, 2022

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Video

» Interview

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

May 4, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.